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Recent studies suggest that the cross-talk between the gut microbiota and human
immune system during the first year of life is an important regulator of the later
development of atopic diseases. We explored the changes in the gut microbiota, blood
regulatory T cells, and atopic sensitization in a birth-cohort of Estonian and Finnish
children followed from 3 to 36 months of age. We describe here an infant Treg phenotype
characterized by high Treg frequency, the maturation of Treg population characterized
by a decrease in their frequency accompanied with an increase in the highly activated
Treg cells. These changes in Treg population associated first with the relative abundance
of Bifidobacterium longum followed by increasing colonization with butyrate producing
bacteria. High bifidobacterial abundance in the neonatal microbiota appeared to be
protective, while colonization with Bacteroides and E. coli was associated with later
risk of allergy. Estonian children with lower risk of IgE mediated allergic diseases than
Finnish children showed an earlier maturation of the gut microbiota, detected as earlier
switch to an increasing abundance of butyrate-producing bacteria, combined with an
earlier maturation of Treg cell phenotype and total IgE production. The children with
established allergic diseases by age 3 showed a decreased abundance of butyrate
producing Faecalibacterium. These results suggest that as well as the maintenance of
a bifidobacterial dominated gut microbiota is important during the first weeks of life, the
overtake by butyrate producing bacteria seems to be a beneficial shift, which should not
be postponed.
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INTRODUCTION
Our understanding of the cross-talk between the gut microbiota
and human immune system during the time when allergic
sensitization develops is limited, although accumulating evidence
indicates that the gut microbiome plays a pivotal role in the
regulation of allergic immune responses (1–8). The composition
of the gut microbiome is determined by our microbial
environment, dietary factors, and genetic background (9). The
evidence of the mechanisms of the gut microbiome as a regulator
of the immune response is largely based on studies in animal
models showing e.g., that the gut microbiome directly or in-
directly via metabolites is able to modulate the permeability
of the intestinal epithelium (10–12), and the differentiation
and function of effector and regulatory T cells (Treg cells)
(13–21), which could further influence the development of
immune-mediated diseases, including allergic, inflammatory,
and autoimmune diseases. In prospective studies of children,
indirect in vitro based evidence suggests that metabolites
of the gut microbiome from the infants with high risk of
atopic diseases could indeed modulate Treg cell phenotype (6).
Arrieta et al. showed that reduced levels of fecal acetate and
dysregulation of enterohepatic metabolites was accompanied
with the gut microbiome changes predicting the risk of asthma
in CHILD cohort (5). Thus, although the altered gut microbiota
composition has been associated with allergic responses in
children, the understanding of the mechanisms linking the gut
microbiota and altered immune deviation is limited in humans.
To investigate the relationship between the development
of the intestinal microbiota, circulating Treg cells, and IgE
sensitization against environmental allergens, we obtained
repeated blood and feces samples during the first 3 years of
life from a cohort of infants living in Estonia or Finland, the
neighboring countries with distinct differences in the standard
of living1,2 and incidence of allergic diseases (e.g., 12 month
prevalence of asthma 9.3 vs. 19.0 %) (22, 23). We found that
the composition of the neonatal gut microbiota associated with
later risk of allergic sensitization and allergic diseases. Our study
further shows that the maturation of the circulating Treg cells
included an increase in the highly activated Treg cells, which
was associated with the relative abundance of Bifidobacterium
longum and colonization with butyrate producing bacteria, and
this maturation process of the gut microbiota and Treg cells
was delayed in Finnish children with a higher risk of IgE
mediated allergic sensitization and diseases in comparison to
Estonian children.
MATERIALS AND METHODS
Study Subjects
We studied a subgroup of Estonian and Finnish children
participating in the DIABIMMUNE (Pathogenesis of type
1 diabetes: testing the hygiene hypothesis) study (Estonia;
n = 85; 43/42 and Finland; n = 76; 42/34 male/female).
These index cases carried HLA conferred genetic risk for
1http://apps.who.int/nha/database
2http://wdi.worldbank.org
type 1 diabetes and celiac disease as previously described
(24) High-risk genotype (DRB1∗03-DQA1∗05-DQB1∗02
and DRB1∗0401/2/4/5-DQA1∗03-DQB1∗03:02 haplotypes)
was found in 12, moderate-risk genotypes in 52 (either one
of the high-risk haplotypes or, DRB1∗04:01/2/5-DQA1∗03-
DQB1∗03:02 with a neutral haplotype), slightly increased risk
genotypes in 92 (either the DRB1∗04:04-DQA1∗03-DQB1∗03:02
or DRB1∗03-DQA1∗05-DQB1∗02 haplotype with a neutral
haplotype), and neutral haplotypes in 5 children. Neutral
haplotypes are all other except the protection associated
haplotypes DQB1∗02, 03:01 or 06:02, or any of the risk
haplotypes. Of all the infants 74 Estonian and 71 Finnish
children (38/36; 40/31 male/female) were born vaginally. The
present study was conducted according to the guidelines of
the Declaration of Helsinki, and was approved by the ethical
committees of both study centers, and written informed consent
was obtained from the children’s parents. The number of study
subjects and samples analyzed in the different assays are given in
Supplementary Table 1.
Flow Cytometry Analysis of Circulating
Regulatory T-Cells
We analyzed the phenotype of peripheral blood regulatory T-cells
in fresh heparinized blood samples obtained at the age of 3, 6,
12, 24, and 36 months (Supplementary Table 1). At least 1 ×
106 events were acquired from each sample on a FACSCaliburTM
and analyzed with the FlowJoTM software. The samples were
compensated post acquisition with FlowJoTM software. The
monoclonal antibodies are shown in Supplementary Table 2. To
assess the number of circulating CD4+CD25highFOXP3+ T
cells in the samples, we gated first CD4+ cells, and then the
CD25+CD127–/lo population. The expression of FOXP3 protein
was analyzed in these cell populations. CD4+CD25highFOXP3+
expression was quantified as median fluorescence intensity (MFI)
in arbitrary units (AU) after subtraction of the negative-control
antibody intensity. Intensity values over the 97.5 percentile of the
negative-control antibody were regarded as positive. Intensities
were calibrated to a set of particles containing known amounts of
fluorescein isothiocyanate.
Gene Expression Based Phenotypic
Analysis of Circulating Regulatory T-Cells
We performed RT-qPCR analysis of enriched circulating
regulatory T-cells at 6, 18, and 36 month samples
(Supplementary Table 1). The product information for the
reagents used is shown in Supplementary Table 2. Enrichment
of Treg cells was made according to the manufacturer’s
instructions using MACS CD25+CD49d– magnetic beads with
the exception that the magnetic labeling of CD25+ regulatory
T cells, which was titrated to 2.5 µl of CD25 MicroBeads II
per 107 total cells for improved cell purity. In addition, the
second enrichment elution with the MS column was omitted
as it resulted in too high yield loss, resulting in mean 87.7%
purity of the enriched Treg cells. An additional wash with
PBS was added before the pellets were frozen at −70◦C in
RLT-lysis buffer for subsequent RT-qPCR analysis. Total RNA
from purified Tregs was isolated with the Qiagen RNeasy Plus
Micro kit according to the manufacturer’s instructions. cDNA
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was synthesized using the random hexamer priming of the
High Capacity cDNA Reverse Transcription kit according to
the manufacturer’s instructions. Real time PCR was performed
with TaqMan Fast master Mix and StepOne Plus instrument.
TaqMan Gene Expression Assays were used for real time PCR
amplification of FOXP3, TGF-beta1, Helios, GATA-3, CTLA-4,
IL-10, and IFN-γ. The endogenous reference used was the gene
ribosomal 18S. To analyze the relative amount of mRNA of the
gene of interest a comparative 11 cycle threshold (Ct) method
was used. An in-house control sample (calibrator sample) was
used to control inter-assay variation. The calibrator sample
was prepared from the phytohaemagglutinin-stimulated human
PBMC derived RNA.
Total and Allergen-Specific IgE Analysis
Total IgE and allergen-specific IgE concentrations were analyzed
from serum samples (Supplementary Table 1) at the age of 6,
18, and 36 months by using the ImmunoCAP fluoroenzyme
immunoassay (Supplementary Table 2). IgE to egg, cow’s milk,
house dust mite, cat, timothy grass, and birch, as well as total
IgE concentrations were analyzed at the age of 6 months. Peanut
was added to the panel at the age of 18 months and dog at the
age of 36 months. The children were classified into four groups
based on their clinical allergy diagnosis and allergen-specific IgE
values: (A) No signs of allergy (no clinical diagnosis, no specific
IgE responses); (B) IgE-sensitization during the study period, up
to 36 months of age (no clinical diagnosis, at least one specific
IgE response); (C) sensitized, up to the time point analyzed (no
clinical diagnosis, at least one specific IgE response); (D) clinical
non-IgE allergy [clinical diagnosis, no specific IgE response (25)];
and (E) clinical IgE allergy (clinical diagnosis and a specific IgE
response to the same allergen).
Analysis of Microbiota
Total DNA was extracted from a 0.25 g fecal sample using
the repeated bead beating method described in detail by Yu
and Morrison (26), with a number of modifications. In brief,
four 3mm instead of 0.5mm glass beads were added during
the homogenization step. Bead beating was performed using
a Precellys 24 at 5.5 beats per millisecond in three rounds of
1min each with 30 s pauses at room temperature in between.
The incubation temperature after the bead beating was raised
from 70 to 95◦C. Importantly, protein precipitation with 260 µl
of ammonium acetate was carried out twice instead of only once.
Elution of DNA from the purification columns was done twice.
Columns from the QiaAmp Stool Kit were replaced by those
from the QIAamp DNA Stool Mini Kit. The V3–V4 region of the
16S rRNA gene was amplified from the fecal DNA by polymerase
chain reaction (PCR) using modified 341F and 806R primers
with a 6 nucleotide barcode on the 806R primer. The sequence
of the 341F primer and the 806R primer was aatgatacggcg
accaccgagatctacactctttccctacacgacgctcttccgatctNNNNCCTACG
GGAGGCAGCAG & caagcagaagacggcatacgagatCGTGATgtgact
ggagttcagacgtgtgctcttccgatctGGACTACHVGGGTWTCTAAT,
respectively, where lowercase letters denote adapter sequences
necessary for binding to the flow cell, underlined lowercase
are binding sites for the Illumina sequencing primers, bold
uppercase highlight the index sequences as reported by Bartram
et al. (27) and regular uppercase are the V3–V4 region primers
(341F on for the forward primers and 806R for the reverse
primers). The inclusion of four maximally degenerated bases
(“NNNN”) maximizes diversity during the first four bases of the
run. Reaction conditions consisted of an initial 94◦C for 3min
followed by 32 cycles of 94◦C for 45 s, 50◦C for 60 s, and 72◦C
for 90 s, and a final extension of 72◦C for 10min. An agarose gel
confirmed the presence of product (band at ∼465 base pairs)
in successfully amplified samples. The remainder of the PCR
product (∼45 µl) of each sample was mixed thoroughly with 25
µl Agencourt AMPure XP magnetic beads and were incubated at
room temperature for 5min. Beads were subsequently separated
from the solution by placing the tubes in a magnetic bead
separator for 2min. After discarding the cleared solution the
beads were washed twice by resuspending the beads in 200 µl
freshly prepared 80% ethanol, incubating the tubes for 30 s in
the magnetic bead separator and subsequently discarding the
cleared solution. The pellet was subsequently air dried for 15min
and resuspended in 52.5 µl 10mM Tris HCl pH 8.5 buffer. Fifty
microliter of the cleared up solution is subsequently transferred
to a new tube. The DNA concentration of each sample was
measured using a Qubit R© 2.0 fluorometer and the remainder
of the sample was stored at −20◦C until library normalization.
Library normalization was done the day before running samples
on the MiSeq by making 2 nM dilutions of each sample. Samples
were pooled together by combining 5 µl of each diluted sample.
Ten microliter of the sample pool and 10 µl 0.2M NaOH were
subsequently combined and incubated for 5min to denature
the sample DNA. To this 980 µl of the HT1 buffer from the
MiSeq 2 × 300 kit was subsequently added. A denatured diluted
PhiX solution was made by combining 2 µl of a 10 nM PhiX
library with 3 µl 10mM Tris HCl pH 8.5 buffer with 0.1%
Tween 20. These 5 µl were mixed with 5 µl 0.2M NaOH and
incubated for 5min at room temperature. The resulting 10 µl
were subsequently mixed with 990 µl HT1 buffer. One hundred
and fifty microliter of the diluted sample pool is combined
with 50 µl of the diluted PhiX solution and was further diluted
by adding 800 µl HT1 buffer. Six hundred microliter of the
prepared library was loaded into the sample-loading reservoir of
the MiSeq 2× 300 cartridge.
Statistical Analysis
MiSeq sequencing pipeline and statistical analysis Software that
was used to analyze the data received from Illumina paired-
end sequencing, included PANDAseq (28), QIIME (29) and ARB
(30). Paired-end reads that were shorter than 400 BP or longer
than 500 BP were discarded by PANDAseq. Statistical analyses
were performed on the family, genus and species level. QIIME
identified sequences down to the Family and Genus level while
ARB was used for most genera (31, 32), as is typically possible for
most fecal bacteria using 16S (31, 32), to identify sequences down
to the species level as earlier described by de Goffau et al. (33,
34) using the latest SILVA reference database (35). Importantly,
species level resolution was achieved for species from the
Bifidobacterium genus. Principal component analysis (PCA) was
performed to find clusters of similar groups of samples or species.
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PCA is an ordination method based on multivariate statistical
analysis that maps the samples into a reduced number of relevant
dimensions of variability. The hierarchical clustering analysis was
performed with the Hierarchical Clustering Explorer 3.5. The
Simpson index was used as a measure of microbial diversity.
Non-parametric tests were used, as microbial abundances are
rarely normally distributed.
The Mann-Whitney U-test, Spearman correlation analysis
(rs), the Wilcoxon or χ2 tests were used as indicated. The use
± indicates that a standard deviation is given. All tests were
two-tailed and a p < 0.05 was considered to indicate statistical
significance. All statistical analyzes were performed using IBM R©
SPSS R© Statistics 20.0. For the analysis of Flow cytometry data
Graph Pad Prism 5 software was used.
RESULTS
Maturation Steps of Treg Cells During the
First 3 Years of Life
To investigate the early maturation of Treg cells we followed
the characteristics of blood Treg cells at the ages of 3, 6, 12, 24,
and 36 months in the Estonian and Finnish children. During
the first year of life, the numbers of blood Tregs (CD4+CD127–
/loCD25high) as well as their FOXP3 protein expression was
high, a drop occurred in the relative numbers of Tregs and their
FOXP3 expression after 12 months of age (Figures 1A,B). At the
same time when the frequency of blood Treg cells decreased, the
proportion of highly activated TregFOXP3high cells increased
(Figures 1C,D), particularly in the Finnish children (Figure 1D).
Similarly, the expression of FOXP3, Helios, TGF-beta1, CTLA-
4, and GATA-3 transcripts in Tregs decreased from 6 to 18
months and then increased to 36months (Figure 1E). Our results
revealed a two-step maturation process in the circulating Treg
cells: a decrease in the proportion of Treg cells followed by an
increase in the highly activated Treg cells, which are reported to
show enhanced suppressive activity (36–40).
Bifidobacterial Composition at 3 Months
Shapes Treg Cells
We hypothesized that gut colonization could drive the changes
in the Treg cell population. In 16S rDNA sequencing of
fecal samples, bifidobacteria comprised the most dominant
microbial group at 3 and 6 months (Supplementary Figure 1).
Principal component 1 (PC1, variance of 51%) differentiated
the children with a normal bifidobacteria dominated infant
microbiota and those with an aberrant microbiota at 3 months
(Figure 2A). A shift toward microbiota dominated by butyrate
producers occurred subsequently (Supplementary Figure 1),
and this correlated with the changes in the FOXP3 intensity in
Treg cells (Figure 2B).
At 3 months of age, PC2 (16%), which is described by the
abundance of Bifidobacterium breve minus the abundance of B.
longum, showed a positive correlation with the relative numbers
of Treg cells (p = 0.006; rs = 0.40). Also, the linear combination
of these bifidobacterial species (B. breve—B. longum) correlated
with the numbers of Treg cells at 3 months (p = 0.002; rs =
0.44), and further later at 6 and 12 months (p = 0.015; rs = 0.33;
and p = 0.018; rs = 0.35, respectively) suggesting that the initial
bifidobacterial composition at 3 months has a long-term effect on
Treg cell numbers (Figure 2C).
The proportion of highly activated TregFOXP3high cells at
3 months showed an association with PC4 (12%) (Figure 2D),
which was almost totally defined by the abundance of B. longum
minus the amount of B. pseudocatenulatum (p < 0.001; rs =
0.80), and consequently B. longum minus B. pseudocatenulatum
associated with the proportion of TregFOXP3high cells (p =
0.007; rs= 0.40).
According to our results, bifidobacterial species, as suggested
by earlier studies (21, 41–43), play an important role in shaping
the Treg cell population, and the relative abundance of B. longum
in the neonatal microbiota seems to be a promoter of Treg cell
maturation, such as the subsequent decrease in the Treg numbers
and the increase in the relative numbers of highly activated
TregFOXP3high cells.
Delayed Maturation of Microbiome and
Treg Cells in Finnish Children
We had a unique opportunity to compare the development of
Treg cells between Estonian and Finnish children. At 3 months,
Estonian children had more highly activated TregFOXP3high
cells in comparison to Finnish children (Figure 3A) in whom
an increase in activated TregFOXP3high cells occurred after 3
months of age (Figure 1C). Furthermore, a positive correlation
between FOXP3 andCTLA-4 transcripts, which reflect functional
activity of Tregs, was seen in Estonian children earlier, at the
age of 6 months (p = 0.008; rs = 0.59 in Estonian children
and p = ns in Finnish children), while this kind of correlation
between FOXP3 and CTLA-4 developed later in Finnish children
and was seen at the age of 3 years (p < 0.001 for both at
36 months, rs = 0.58 and rs = 0.70 for Estonian and Finnish
children, respectively). These findings suggest that the phenotype
of blood Tregs remains longer immature during early life in
Finnish children in comparison to Estonian children.
Also differences in the gut microbiota at 3 months of age
was seen between Estonian and Finnish children, when the
abundance of B. breve minus B. longum was higher in Finnish
children (p < 0.001). At 18 months, PC2 (11%), which describes
the abundance of well-established butyrate producers in relation
to bifidobacteria, differentiates Estonian and Finnish children
(Figure 3B). Estonian children had a lower bifidobacterial
abundance than Finnish children (13% vs. 26%, p = 0.02), and
a higher abundance of butyrate producing bacteria (40% vs.
29%, p = 0.01, Figure 3B) (for the butyrate producing bacteria
see Supplementary Table 3). A drop in bifidobacteria took place
only after 18months in Finnish children. Despite of this, Estonian
children scored higher at 36 months in PC1, which represents
67% of variation and primarily reflects the abundance of butyrate
producers (Figure 3C). Consequently, a higher abundance of
butyrate producers was found in Estonian children at 36 months
(45% vs. 36%, p = 0.02) indicating a more mature microbiome
composition. In addition, Finnish children showed a higher
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FIGURE 1 | Age-related changes in the blood regulatory T cell (Treg) population from the age of 3 to 36 months in Estonian and Finnish children. (A) The frequency
(%) of Treg cells in the CD4+ cell population. (B) FOXP3 expression as the median fluorescence intensities (MFI) in Treg cells. (C) The gating for the identification of
TregFOXP3High cells. (D) The proportion (%) of TregFOXP3High cells in the Treg population. Sample sizes for figures (A,B,D) are n = 111 at 3 mo; n = 45 at 6 mo; n
= 100 at 12 mo; n = 84 at 24 mo; and n = 92 at 36 months of age. Medians are shown as horizontal lines (E). The expression of Treg activation markers (mRNA) in
Treg cells in all children studied. The columns are showing the medians with ranges. White columns indicate 6 month, light gray columns 18 month, and dark gray
columns 36 month samples. The vertical dotted line indicates the use of two different scales on the y-axis. The age of the children (months), are marked on the x-axes
in (A,B,D) and the different activation markers in (E) (n = 33 at 6 mo; n = 96 at 18 mo; and n = 80 at 36 months of age). Wilcoxon test (two-sided) was used for
comparisons. P-values in the figure are shown as ****p < 0.0001; ***p < 0.001; **p < 0.01 and *p < 0.05.
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FIGURE 2 | Relation between the maturation of the gut microbiota composition and Treg phenotype. (A) Principal component analysis on all samples on the genus
level shows the age-related maturation of gut microbiome. Principal component 1 on the x-axis (from 0 to 1) accounts for 51% of the variation in the data while
principal component 2 on the y-axis accounts for 16%. Samples at 3 and 6 months are either found in the lower right corner (normal bifidobacteria-dominated
microbiota) or in the left (red circle) representing an aberrant microbiota largely devoid of bifidobacteria and instead replaced by a combination of Escherichia coli,
Bacteroides, Ruminococcus gnavus, and/or clostridia (pink circle). The normal bifidobacteria-dominated microbiota (lower right corner) usually is the basis for future
development (blue arrow) into a more complex adult-like configuration. (B) A graphical representation of FOXP3 expression levels in the whole Treg population in
relation to the gut microbiota development. (C) A graphical representation of the influence of the bifidobacteria composition at 3 months of age on Treg numbers at 3,
6, 12, 24, and 36 months. Children with a Bifidobacterium breve—Bifidobacterium longum abundance lower than −1% at 3 months are depicted on the left of each
column and those with scores higher than −1% are depicted on the right, with median as a horizontal line in the boxes. P-values (top) were not based on the binary
division of 1% but on the actual B. breve—B. longum abundance per sample and their corresponding Treg-value using a Spearman rho’s correlation test. The value of
−1% was chosen to specifically showcase those children who have B. longum in a non-insignificant amount and have more of it than B. breve. (D) The number of
Treg cells with high expression of FOXP3 shows association with PC4, which is described by the relative abundances of B. longum and B. pseudocatenulatum at the
age of 3 months and accounts for 12% of the variation. The arrows in the image are a direct representation of the Spearman correlation coefficient of each of the
indicated factors with the respective principal components. The green diamonds (♦) represent TregFOXP3High frequencies >4.5%; yellow triangles (N) 3%<
TregFOXP3High >4.5%; and red circles (•) TregFOXP3High frequencies <3%. Estonian children are marked with an (×). The red circle indicates samples, which
represent an aberrant microbiota composition, and hardly contain bifidobacteria as also illustrated in (A).
abundance of Bacteroides at both 12 and 18 months of age (9.7%
vs. 2.4%, p= 0.003 and 6.6% vs. 1.6%, p= 0.008).
Neonatal Gut Microbiota Predicts Allergic
Response
Next, we studied the association between the development of
circulating allergen-specific IgE antibodies and their association
with the composition of gut microbiota. We found that gut
microbiota composition at 3 months of age, but not after
that, showed an association with atopic sensitization, i.e., the
development of allergen-specific IgE later in life. PC2 (genus
level) shows association with atopic sensitization (Figure 4A)
and it is nearly perfectly described by the abundance of
bifidobacteria minus the abundances of Bacteroides and E. coli
at 3 months of age (p < 0.001, rs = 0.96), which further shows
an inverse association with atopic sensitization (Figure 4B)
and represents a clear vector associated with the number of
allergen-specific IgEs (p = 0.012), the age of the first allergen-
specific IgE (p = 0.039) and also the diagnosis of allergies
(p =0.012). Furthermore, bifidobacteria and in particular the
relative abundance of B. longum at 3 months showed an inverse
association with atopic sensitization, the number of allergen-
specific IgEs and the development of allergy (p = 0.023, p =
0.026, p= 0.022). As a conclusion, high abundance of Bacteroides
and E. coli at the expense of the abundance of bifidobacteria in
early infancy increased the risk of atopic sensitization and clinical
allergy later in childhood.
At the age of 18 months, the expression of FOXP3, GATA-3,
and CTLA-4 in Tregs was higher in the children with allergen-
specific IgE sensitization without signs of clinical allergy when
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FIGURE 3 | The differences in Treg cells at 3 months and gut microbiome between Estonian and Finnish children at 18 and 36 months of age. (A) The frequencies of
TregFOXP3high cells in the Treg population is higher at 3 months in Estonian (n = 56) than Finnish children (n = 55). Median values are shown with a horizontal line.
The P-value was calculated with Mann-Whitney U (two-sided). (B) PC2 at 18 months is mostly driven by the amount of butyrate produces minus the amount of
bifidobacteria (X-axis), as can be seen by the strong positive correlation. Estonian children score higher on PC2 (18 month samples) than Finnish children, which
indicates that Estonians have more butyrate producers at 18 months than the Finnish children, while the Finnish children have more bifidobacteria. At 36 months
(C) another pattern is seen, this time described by PC1 (67%). Estonian children on average score higher on PC1 (Y-axis), which in turn is driven mostly by the
abundance of butyrate producers in the 36 month samples (X-axis). Estonian children have on average more butyrate producers than then Finnish at 36 months. The
circles (•) show Estonian and diamonds (♦) Finnish children in these principal component plots.
compared to the children who did not develop clinical allergies
(Figure 4C).
At the end of the follow-up, atopic sensitization correlated (rs
= 0.57; P < 0.001) with PC1 on the genus level, which accounts
for 67% of the variation at 36 months of age, and describes the
abundance of a trophic network of butyrate producers. PC1 is
inversely correlated with the number of allergen-specific IgEs (rs
= −0.50; P < 0.001) (Figure 5A), and atopy (rs = −0.57; P <
0.001), diagnosis of food allergies (rs = −0.58; P < 0.001) and
inhalation allergies (rs=−0.39; P = 0.031).
In children with food allergy, Faecalibacterium (F. prausnitzii)
(Figure 5B), which is directly correlated with PC1 and is one of
the most important butyrate producing groups, was decreased
while the abundance of Mogibacteriaceae (Figure 5C) being
inversely correlated with PC1, was increased.
Increased Total IgE Production in Estonian
Children
Because total IgE levels are considered as a predictive marker
for development of later IgE-sensitization and allergies, we
analyzed the associations between total IgE levels, gut microbiota
composition and characteristics of Tregs. Interestingly, we found
that total IgE levels were higher in Estonian than Finnish children
in the blood samples collected at 6 months (median 8.4, range
2–311 vs. 5.2 range 2–311293.5 kU/L; p = 0.02) and 36 months
(62.4; range 2.41–2956 vs. 25.9; range 1.26–456 kU/L; p = 0.006,
respectively). In Estonian children, total IgE levels at 6 months
did not correlate with later IgE-sensitization or allergies as they
did in Finnish children (p< 0.001, rs= 0.40).
As the dynamic changes in GATA-3 and FOXP3 expression
in Treg cells have been shown to regulate the function of Treg
cells and Th2 immunity (44, 45), we next asked whether GATA-3
mRNA expression in Treg cells is associated with the different
kinetics seen in the maturation of IgE production. Indeed, in
Estonian children, GATA-3 expression in Treg cells at 6 months
correlated positively with total IgE levels at 18months (P= 0.047,
rs = 0.56) while in Finnish children GATA-3 expression level in
Treg cells at 6 months showed an inverse correlation with total
IgE levels at 6 (P = 0.001, rs = −0.77) and later at 18 months
(P = 0.052, rs = −0.55). Similarly, Helios expression (46, 47) in
Treg cells at 6 months correlated negatively with the total IgE
production in Finnish children at 6 and 18 months of age (P =
0.002, rs=−0.75 and P = 0.021, rs=−0.63).
DISCUSSION
In the birth-cohort of Estonian and Finnish children followed
from 3 to 36 months of age, we demonstrate that the composition
of neonatal intestinal microbiota modulates the maturation of
Treg population during the first year of life, and the risk of
allergic diseases later in life. An earlier study in a US cohort
identified a specific neonatal gut microbiota composition, which
is characterized by a lower relative abundance of Bifidobacterium,
Akkermansia, and Faecalibacterium, and a higher relative
abundance of particular fungi, as a risk of atopy and asthma in
a follow-up up to 4 years of age (6). That study also showed
that fecal water extract from high-risk infants compromised
Treg suppressive activity in vitro (6) suggesting that a defective
function of Treg cells could be a factor contributing to the
development of asthma. Those observations together with our
findings support the view that neonatal microbiome is an
important regulator of Treg cells and allergic sensitization. Our
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FIGURE 4 | Relation between atopic sensitization and the gut microbiota composition and Treg phenotype. (A) PC2, as derived from the genus level at 3 months of
age, correlates positively with atopic sensitization during the study period (p = 0.01, rs = 0.34; No sensitization n = 35; sensitization between 0.35 and 0.69 n = 7;
sensitization ≥0.7 n = 13). (B) The abundances of Bacteroides and E. coli. are individually significantly associated with the development of atopic sensitization while
bifidobacteria are protective. When both Gram negative groups are subtracted from the abundance of bifidobacteria the resulting association inversely mirrors the
association of PC2 with atopic sensitization (p = 0.005; rs = 0.37; No sensitization n = 33; Allergen specific IgE level between 0.35 and 0.69 n = 7; Allergen specific
IgE level ≥ 0.7 n = 12). Open circles show Finnish (◦) and black circles show Estonian (•) infants. (C) The expression (mRNA) of activation markers FOXP3, GATA-3,
and CTLA-4 is increased in blood derived Treg cell population at the age of 18 months in the children with IgE sensitization but without clinical allergy. The children
were classified into four groups based on their clinical allergy diagnosis and allergen-specific IgE values: (a) No signs of allergy (no clinical diagnosis, no
allergen-specific IgE responses, n = 46 for FOXP3 and TGFb-1 and n = 45 for GATA-3 and CTLA-4); (b) IgE-sensitization developed during the study period (no
clinical allergy diagnosis, at least one allergen specific IgE response ≥0.35 IU/mL, n = 28); (c) IgE-sensitized at the time of follow-up point (no clinical allergy diagnosis,
at least one allergen specific IgE response ≥0.35 IU/mL, n = 20 for all other and n = 21 for TGFb-1); (d) clinical non-IgE allergy (clinical diagnosis of allergy, no allergen
specific IgE response 45, n = 16); and (e) clinical IgE allergy (clinical diagnosis of allergy and a specific IgE response to the allergen related to the symptoms, n = 6).
The different activation markers are marked on the x-axes. The vertical dotted line indicates the use of two different scales on the y-axis. Medians are marked with a
horizontal line. Mann-Whitney U-test (two-sided) was used for comparisons.
findings together with earlier studies emphasize the importance
of the intestinal colonization during the first weeks or months
of life as a key determinant for the risk of atopic deviation,
and particularly the maintenance of a bifidobacterial dominated
microbiome (2–7). Altogether, these studies suggest that the
window of opportunity for the primary prevention of atopic
diseases leading to asthma may be narrow, from birth up to 3
months of age.
In addition, we found that Finnish children, having higher
risk of IgE mediated allergic diseases, show signs of delayed
maturation of the gut microbiota and Treg cell phenotype when
compared to Estonian children. Immature phenotype of the gut
microbiota was found to be a risk factor for later allergic asthma
in a Danish COPSAC cohort study (7). Accordingly, as well as
the maintenance of a bifidobacterial dominated gut microbiota
is important during the first weeks of life, the overtake by
butyrate producing bacteria seems to be a beneficial shift, which
should not be postponed. Butyrate is the main energy source
for colonic epithelial cells (48), and it regulates the assembly
of tight junctions and gut permeability (49). Thus, the switch
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FIGURE 5 | Relation of the gut microbiota composition and allergy at 36 months of age. (A) A negative correlation is seen between PC1 and the number of
allergen-specific IgEs at 36 months of age (p < 0.001, n = 30), (B) Decreased abundance of the butyrate producer Faecalibacterium prausnitzii in children with food
allergy at 36 months of age (p = 0.001; No food allergy n = 19, Food allergy n = 11). (C) Increased abundance of Mogibacteriaceae in children with food allergy at the
age of 36 months (p = 0.006, n = 19 and 11, respectively). Medians are marked with a horizontal line.
to an increasing abundance of butyrate producing bacteria may
facilitate the maturation of the gut barrier mechanisms during
the early life (50). Also in children with already established
allergic diseases, we found a decrease in butyrate producing
Faecalibacterium, which is in agreement with the findings in
the American Gut Project (51). Recent studies suggest the
importance of butyrate in the regulation of allergic airway
inflammation by limiting eosinophilic inflammation (52) and
type 2 innate lymphoid-cell proliferation and function (53).
According to our findings, remarkable age-related changes
occur in the phenotype of the circulating Treg population during
the first years of life, and these changes are tightly linked to
the maturation of the intestinal microbiota. The neonatal Treg
phenotype is characterized by the high frequency of circulating
Treg cells, which is in agreement with an earlier study reporting
increased numbers of Tregs in infants compared to adults (54).
An increase in Treg cells after birth is characterized by a high
frequency of naïve Treg cells (39, 40). The high ratio of B. breve
vs. B. longum in the gut microbiota at 3 months of age showed
association with high Treg numbers during the whole first year
of life emphasizing the long-term effects of the neonatal gut
microbiome. The following step of Treg maturation, i.e., the
emergence of a highly activated Treg cell phenotype with high
expression of FOXP3, TGF-beta1 and Helios showed instead
an association with the high relative abundance of B. longum.
Indeed, bifidobacteria species have been demonstrated to affect
the induction of FOXP3 Treg cells (21). B. longum can activate
Treg cells in newborn and adult mice, whereas B. breve shows an
effect on regulatory T cells only in newborn mice. Furthermore,
supplementation with B. longum protected against airway
inflammation in an animal model (21). Also in humans, feeding
a B. longum strain induced FOXP3 expressing regulatory T cells
(55). The beneficial effects of B. longum 35624 has been suggested
to be mediated by surface associated exopolysaccharide (41). A
recent study showed that administration of B. longum changes
the microbiota composition and thus metabolic mediators (42).
Importantly, it seems that the effects of bifidobacteria on Tregs
are dependent on species and strains, which should be considered
in the design of possible probiotic treatments as suggested by
others as well (43).
Whereas, the abundance of B. longum was an important
determinant of Treg cell maturation during early infancy,
the maturation of Treg cells after the first year of life, i.e.,
increasing numbers of highly activated Treg cells, showed a
strong association with the increasing abundance of butyrate
producing bacteria, and thus increasing diversity of the intestinal
microbiome, which is likely contributed by changes in the
diet. Our findings linking the temporal changes in the gut
microbiome with Treg cell maturation are supported by an
earlier study showing that Treg maturation between 18 and
36 months of age includes dynamic changes in the homing
receptor pattern from a4b7-integrin, a gut homing receptor,
to CCR4, which attract T-cells to non-gastrointestinal tissues
(40). Accordingly, the early maturation of Tregs in the infants
seems to be driven by intestinal antigens, such as diet and
microbiome derived antigens. The effects of gut microbiomemay
be local in the intestine, such as reported for the extrathymic
effects of butyrate on Treg differentiation (13, 19). On the other
hand, changes in the gut microbiota and metabolites during
colonization could affect the maturation process of Treg cells
in thymus, as it has been shown that changes in the intestinal
microbiota induced by antibiotic treatment can affect the thymus
microenvironment, namely the T cell receptor repertoire of
thymic Treg cells (56).
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We had an opportunity to compare Finnish and Estonian
children who live in a different environment regarding the
risk for allergy and standard of living. We observed several
signs of delayed maturation of Treg cells in Finnish children in
comparison the Estonian children, such as a lower frequency
of the highly activated Treg cells at 3 months of age, and later
development of the correlation between FOXP3 and CTLA-
4 transcripts regulating immune suppression activity in the
Treg cell population. Related differences in the gut microbiota
between Estonian and Finnish children were evident, i.e.,
higher ratio of B. longum vs. B. breve at 3 months, and an
earlier switch from bifidobacteria dominated microbiota to a
microbiota with increasing numbers of butyrate producers in
Estonian children.
Finally, despite having less IgE mediated allergies, Estonian
children had higher total IgE levels than Finnish children
indicating an earlier maturation of IgE production, which
takes place during the first 5 to 6 years of life when the
IgE levels reach adult levels (57). Differential maturation
of IgE production between populations has been observed
earlier indicating the importance of environmental factors
(58). In Estonian children high total IgE did not associate
with IgE sensitization and the risk of allergic diseases
like in Finnish children suggesting differential regulation of
IgE responses. In Estonian children GATA-3 expression in
Tregs at 6 months of age was associated with total IgE
production and correlated with the expression of CTLA-
4, which is a functional mediator of immune suppression.
Interestingly, the expression of FOXP3, CTLA-4, and GATA-3
in Treg cells were increased in children with IgE sensitization
who did not develop clinical allergy, which suggests that a
transcriptional signature supporting Treg suppression activity,
i.e., FOXP3 and CTLA-4, could provide homeostasis despite
of up-regulation of Th2 transcription factor GATA-3 in
Treg cells (59).
We recognize that our study has limitations due to its
observational nature, and due to the possible confounding
factors, such as reported higher frequency of infections, and
use of antibiotics and antipyretic drugs in Finnish children
(60). On the other hand, it is among the first studies, in
which the immunological maturation and changes in the
composition of the gut microbiota are monitored in healthy
children at the same time during the first years of life.
Similar kind of temporal changes in the gut microbiota as
seen in our cohort were described recently in TEDDY cohort
(61, 62). Also several observations we made here, linking the
immunological changes with the maturation of gut microbiota,
are mechanistically supported by the earlier literature showing
more direct evidence, which has been possible to generate
in animal models. In this longitudinal follow-up study, we
were able to reveal that delayed maturation of the gut
microbiota, Treg cell population and total IgE production are
characteristics of children living in an environment with high
risk of allergic diseases, which encourages treatments promoting
healthy maturation of gut microbiota aimed at the prevention
of allergies.
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